[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.124.106. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
September 9, 1998

Thalidomide Approved for Erythema Nodosum Leprosum

Author Affiliations
 

Not Available

Not Available

JAMA. 1998;280(10):872. doi:10.1001/jama.280.10.872

The FDA has approved thalidomide (Thalomid, Celgene Corp, Warren, NJ), with unprecedented restrictions on distribution, for the treatment of one form of leprosy—either for acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) or as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. It is not indicated as monotherapy for ENL treatment in the presence of moderate to severe neuritis.

First Page Preview View Large
First page PDF preview
First page PDF preview
×